Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates
Regeneron (REGN) came out with quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share. This compares to earnings of $9.55 per share a year ago.
Regeneron Pharma's first-quarter results miss on lower Eylea demand
Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket trading.
What Analyst Projections for Key Metrics Reveal About Regeneron (REGN) Q1 Earnings
Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
Analysts Estimate Regeneron (REGN) to Report a Decline in Earnings: What to Look Out for
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron signs over $3 billion deal with contract drugmaker to boost US manufacturing
Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. manufacturing capacity.
Regeneron: Still A Biotech Juggernaut
Regeneron's stock has dropped 40% due to EYLEA's IP issues, but strong financials and pipeline assets bolster optimism for long-term growth. Dupixent's robust sales growth and potential new indications position it as Regeneron's primary growth engine, overshadowing EYLEA. Regeneron's oncology platform, led by Libtayo and promising bispecific antibodies, is poised to be a significant growth driver in the next decade.
RFK Jr. 'needs a lot of help and expertise' on science, says Regeneron CEO
Regeneron CEO Leonard Schleifer on Tuesday said that Health and Human Services Secretary Robert F. Kennedy Jr.
Regeneron CEO Leonard Schleifer on tariffs: Let's make sure the Europeans pay their fair share
Regeneron founder, chair and CEO Leonard Schleifer joins 'Squawk Box' to discuss the impact of President Trump's tariff policies on biotech and pharmaceuticals, his thoughts on HHS Secretary RFK Jr., fixing the health care industry, and more.
Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led to increased competition and pricing pressures, impacting the company's revenue and profit margins. Despite these challenges, Regeneron's other drugs, particularly Dupixent and Libtayo, show promise for future growth and revenue generation.
Regeneron Pharmaceuticals, Inc. (REGN) Leerink Partners 2025 Global Healthcare Conference Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET Company Participants Ryan Crowe - SVP, IR & Strategic Analysis Chris Fenimore - CFO Conference Call Participants David Risinger - Leerink Partners David Risinger All right. So we're going to get started.
1 Dividend Stock Down 30% to Buy and Hold for the Next Decade
Biotech giant Regeneron Pharmaceuticals (REGN 1.30%) saw its fortunes reversed last year. Though the drugmaker had performed well since the beginning of the decade, it encountered issues that sank its stock price, mostly related to one of its biggest growth drivers (more on that below).
